727 related articles for article (PubMed ID: 21079577)
21. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.
Ambrogi F; Biganzoli E; Querzoli P; Ferretti S; Boracchi P; Alberti S; Marubini E; Nenci I
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):781-90. PubMed ID: 16467089
[TBL] [Abstract][Full Text] [Related]
22. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
23. MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential (review).
Zhang K; Zhang Y; Liu C; Xiong Y; Zhang J
Int J Oncol; 2014 Sep; 45(3):950-8. PubMed ID: 24913679
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.
Liu WH; Yeh SH; Lu CC; Yu SL; Chen HY; Lin CY; Chen DS; Chen PJ
Gastroenterology; 2009 Feb; 136(2):683-93. PubMed ID: 19027010
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Li XF; Yan PJ; Shao ZM
Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
27. [Relative indicators for disease outcome in breast carcinoma].
Schnürch HG
Praxis (Bern 1994); 1998 Apr; 87(15):504-10. PubMed ID: 9608245
[TBL] [Abstract][Full Text] [Related]
28. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
29. Micromarkers: miRNAs in cancer diagnosis and prognosis.
Ferracin M; Veronese A; Negrini M
Expert Rev Mol Diagn; 2010 Apr; 10(3):297-308. PubMed ID: 20370587
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
31. Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues.
Khoshnaw SM; Powe DG; Ellis IO; Green AR
Methods Mol Biol; 2011; 755():119-42. PubMed ID: 21761299
[TBL] [Abstract][Full Text] [Related]
32. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management.
Lowery AJ; Miller N; McNeill RE; Kerin MJ
Clin Cancer Res; 2008 Jan; 14(2):360-5. PubMed ID: 18223209
[TBL] [Abstract][Full Text] [Related]
33. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
Lin Z; Reierstad S; Huang CC; Bulun SE
Cancer Res; 2007 May; 67(10):5017-24. PubMed ID: 17510434
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect.
Lee SE; Kim SJ; Youn JP; Hwang SY; Park CS; Park YS
J Pineal Res; 2011 Oct; 51(3):345-52. PubMed ID: 21615491
[TBL] [Abstract][Full Text] [Related]
35. MicroRNAs: toward the clinic for breast cancer patients.
Ferracin M; Querzoli P; Calin GA; Negrini M
Semin Oncol; 2011 Dec; 38(6):764-75. PubMed ID: 22082762
[TBL] [Abstract][Full Text] [Related]
36. 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells.
Shah MY; Pan X; Fix LN; Farwell MA; Zhang B
J Cell Physiol; 2011 Jul; 226(7):1868-78. PubMed ID: 21506117
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
Andorfer CA; Necela BM; Thompson EA; Perez EA
Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
[TBL] [Abstract][Full Text] [Related]
38. [MicroRNAs and prostate cancer].
Yang CH; Zhang CN
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):844-9. PubMed ID: 21171273
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs.
Wang L; Wang J
Oncogene; 2012 May; 31(20):2499-511. PubMed ID: 21963843
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis.
Harquail J; Benzina S; Robichaud GA
Cancer Biomark; 2012; 11(6):269-80. PubMed ID: 23248185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
